Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Perineural versus intravenous dexamethasone as adjuncts to local anaesthetic brachial plexus block for shoulder surgery
Rosenfeld, David M. , Ivancic, Michael G., Hattrup, Steven J. , Watkins, Amanda , Hentz, J. G., Gorlin, Andrew , Spiro, Joshua, Trentman, Terrence L. , Renfree, Kevin J.

Anaesthesia | February 22, 2016 | Volume: 71 | Issue: 4 | Pages: 380-388

10.1111/anae.13409 | PMID 26899862 Get It

Summary This randomised, double‐blind, placebo‐controlled study compared the effect of perineural with intravenous dexamethasone, both administered concomitantly with interscalene brachial plexus block for shoulder surgery. Patients received 8 mg dexamethasone mixed with ropivacaine in the block injection (n = 42), 8 mg dexamethasone intravenously at the time of the block (n = 37), or intravenous saline (n = 41) at the time of the block. Perineural and intravenous dexamethasone resulted in prolonged mean ( SD ) duration of block to 16.9 (5.2) h and 18.2 (6.4) h, respectively, compared with 13.8 (3.8) h for saline (p = 0.001). Mean (SD) opioid consumption (morphine equivalents) during the first 24 h after postanaesthesia recovery arrival was 12.2 (9.3) mg in the perineural dexamethasone, 17.1 (15.9) mg in the intravenous dexamethasone and 24.1 (14.3) mg in the saline groups (p = 0.001). Dexamethasone via either route reduced anti‐emetic use (p = 0.046). There was no effect on patient satisfaction. These results suggest that both perineural and intravenous dexamethasone are useful adjuncts to ropivacaine interscalene block, with the intravenous route preferred as this avoids the possibility of neural toxicity of dexamethasone.
Tailoring through Technology: A Retrospective Review of a Single Surgeon's Experience with Implant-Based Breast Reconstruction before and after Implementation of Laser-Assisted Indocyanine Green Angiography
Harless, Christin A., Jacobson, Steven R.

The Breast Journal | February 22, 2016 | Volume: 22 | Issue: 3 | Pages: 274-281

10.1111/tbj.12576 | PMID 26899399 Get It

Development and Validation of HealthImpact: An Incident Diabetes Prediction Model Based on Administrative Data
Nori, Vijay S. , Smith, Steven A., Hane, Christopher A. , McCoy, Rozalina G.

Health Services Research | February 21, 2016 | Volume: 51 | Issue: 5 | Pages: 1896-1918

10.1111/1475-6773.12461 | PMID 26898782 Get It

Objective To develop and validate a model of incident type 2 diabetes based solely on administrative data. Data Sources/Study Setting Optum Labs Data Warehouse (OLDW), a national commercial administrative dataset. Study Design HealthImpact model was developed and internally validated using nested case–control study design; n = 473,049 in training cohort and n = 303,025 in internal validation cohort. HealthImpact was externally validated in 2,000,000 adults followed prospectively for 3 years. Only adults ≥18 years were included. Data Collection/Extraction Methods Patients with incident diabetes were identified using HEDIS rules. Control subjects were sampled from patients without diabetes. Medical and pharmacy claims data collected over 3 years prior to index date were used to build the model variables. Principal Findings HealthImpact, scored 0–100, has 48 variables with c‐statistic 0.80815. We identified HealthImpact threshold of 90 as identifying patients at high risk of incident diabetes. HealthImpact had excellent discrimination in external validation cohort (c‐statistic 0.8171). The sensitivity, specificity, positive predictive value, and negative predictive value of HealthImpact >90 for new diagnosis of diabetes within 3 years were 32.35, 94.92, 22.25, and 96.90 percent, respectively. Conclusions HealthImpact is an efficient and effective method of risk stratification for incident diabetes that is not predicated on patient‐provided information or laboratory tests.
The use of ultrasound guidance for perioperative neuraxial and peripheral nerve blocks in children
Guay, Joanne, Suresh, Santhanam , Kopp, Sandra L. , Kopp, Sandra

Cochrane Database of Systematic Reviews | February 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd011436.pub2 | PMID 26895372 Get It

Carbon fiducials for large choroidal melanoma treated with gamma knife radiosurgery
Reynolds, Margaret , Whitaker, Thomas J. , Parney, Ian F. , Kozelsky, Timothy F., Garces, Yolanda I. , Foote, Robert L. , Tryggestad, E., Pulido, José S. , Reynolds, Margaret M, Tryggestad, Erik J, Parney, Ian F , Reynolds, Margaret M

Acta Ophthalmologica | February 20, 2016 | Volume: 94 | Issue: 8 | Pages: No page available

10.1111/aos.12982 | PMID 26893172 Get It

A practical review on carfilzomib in multiple myeloma
Muchtar, Eli , Magen, Hila , Gertz, Morie A. , Muchtar, E

European Journal of Haematology | February 20, 2016 | Volume: 96 | Issue: 6 | Pages: 564-577

10.1111/ejh.12749 | PMID 26893241 Get It

AbstractCarfilzomib, a second‐generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high‐risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.
Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors
Shah, Paras , Moreira, Daniel M. , Okhunov, Zhamshid , Patel, Vinay , Chopra, Sameer , Razmaria, Aria, Alom, Manaf, George, Arvin K. , Yaskiv, Oksana, Schwartz, Michael J. , Desai, Mihir , Vira, Manish , Richstone, Lee, Landman, Jaime, Shalhav, Arieh L., Gill, Inderbir S. , Kavoussi, Louis R., Gill, Inderbir S

Journal of Urology | February 20, 2016 | Volume: 196 | Issue: 2 | Pages: 327-334

10.1016/j.juro.2016.02.075 | PMID 26907508 Get It

Long‐term Outcomes After Osteochondral Autograft Transfer: A Systematic Review at Mean Follow‐up of 10.2 Years
Pareek, Ayoosh , Reardon, Patrick J., Levy, Bruce A. , Krych, Aaron J. , Maak, Travis G. , Stuart, Michael J. , Krych, Aaron J

Arthroscopy | February 20, 2016 | Volume: 32 | Issue: 6 | Pages: 1174-1184

10.1016/j.arthro.2015.11.037 | PMID 26906461 Get It

Purpose To evaluate (1) activity level and knee function, (2) reoperation and failure rates, and (3) risk factors for reoperation and failure of osteochondral autograft transfer (OAT) at minimum long‐term follow‐up. Methods A comprehensive review was performed for long‐term outcomes after OAT. Studies reported on activity‐based outcomes (Tegner Activity Scale) and clinical outcomes (Lysholm score and International Knee Documentation Committee score). Reoperation and failure rates, as defined by the publishing authors, were recorded for each study. Modified Coleman Methodology Scores were calculated to assess study methodological quality. Results Ten studies with a total of 610 patients with an average age of 27.0 years at the time of surgery and a mean follow‐up of 10.2 years were included. The mean defect size was 2.6 cm 2 (range, 0.9 to 20.0 cm 2 ). The mean duration of symptoms before surgery was 4.8 years. From preoperative to final follow‐up, International Knee Documentation Committee scores and Lysholm scores improved significantly by 42.4 (95% confidence interval [CI], 31.8 to 53.1, P < .001) and 21.1 (95% CI, 12.2 to 30.0, P < .01), respectively. Tegner score did not improve significantly (0.76, 95% CI, −0.83 to 2.36, P = .35). Overall failure rate was 28% and reoperation rate was 19%. Increased age, previous surgery, and defect size positively correlated with increased risk of failure. Concomitant surgical procedures negatively correlated with failure rate. Conclusions Overall, OAT showed successful outcomes in 72% of patients at long‐term follow‐up. Increased age, previous surgery, and defect size correlated positively with failure rate, whereas success improved with concomitant surgical procedures. Nonetheless, this systematic review is limited by heterogeneity in a surgical technique, lesion and patient characteristics, and reporting of nonstandardized outcome measures. Level of Evidence Level IV, systematic review of Level I‐IV studies.
Antibiotics and onset of functional gastrointestinal disorders
Grover, Madhusudan , Talley, Nicholas J.

Neurogastroenterology & Motility | February 20, 2016 | Volume: 28 | Issue: 3 | Pages: 451-451

10.1111/nmo.12781 | PMID 26891063 Get It

Big Data Transforms Discovery–Utilization Therapeutics Continuum
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Clinical Pharmacology & Therapeutics | February 20, 2016 | Volume: 99 | Issue: 3 | Pages: 250-254

10.1002/cpt.322 | PMID 26888297 Get It

Enabling omic technologies adopt a holistic view to produce unprecedented insights into the molecular underpinnings of health and disease, in part, by generating massive high‐dimensional biological data. Leveraging these systems‐level insights as an engine driving the healthcare evolution is maximized through integration with medical, demographic, and environmental datasets from individuals to populations. Big data analytics has accordingly emerged to add value to the technical aspects of storage, transfer, and analysis required for merging vast arrays of omic‐, clinical‐, and eco‐datasets. In turn, this new field at the interface of biology, medicine, and information science is systematically transforming modern therapeutics across discovery, development, regulation, and utilization.